Peter Angus, Geoffrey McCaughan, and Simone Strasser received minor honoraria from Gilead Sciences for participation in Advisory Boards or Speakers' Bureau.
A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis†
Article first published online: 21 JUL 2008
Copyright © 2008 American Association for the Study of Liver Diseases
Volume 48, Issue 5, pages 1460–1466, November 2008
How to Cite
Angus, P. W., Patterson, S. J., Strasser, S. I., McCaughan, G. W. and Gane, E. (2008), A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post–liver transplantation hepatitis B prophylaxis. Hepatology, 48: 1460–1466. doi: 10.1002/hep.22524
Potential conflict of interest: Dr. Angus advises and received grants from Gilead. Dr. Strasser advises and is on the speakers' bureau of Gilead. Dr. McCaughan advises Gilead.
- Issue published online: 28 OCT 2008
- Article first published online: 21 JUL 2008
- Accepted manuscript online: 21 JUL 2008 12:00AM EST
- Manuscript Accepted: 6 JUL 2008
- Manuscript Received: 22 APR 2008
- Gilead Sciences donated drug and provided unrestricted research support for this study
- 19Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: high resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512–519., , , , , , et al.
- 26Five year follow-up of a randomized study comparing lamivudine vs. lamivudine+HBIG in the prevention of HBV recurrence after liver transplantation [Abstract]. HEPATOLOGY 2005; 42(Suppl): 491A., , , , , .
- 30A prospective study on the safety and efficacy of lamivudine and adefovir prophylaxis in HBsAg positive liver transplantation candidates [Abstract]. HEPATOLOGY 2007; 46(Suppl): 479A., , , , .